Predicine, a Bay Area precision medicine organization, opened a major R&D facility in Shanghai that offers liquid- and tissue biopsy-based precision diagnostics to China. Predicine describes itself as an international precision medicine company that is committed to developing innovative diagnostics, therapeutics and big data in cancer and other serious diseases. Predicine developed the world’s first ctRNA+ctDNA combined liquid biopsy test, called Gene RADAR, which uses a single tube of blood to detect genetic alterations.
